http://news.yahoo.com/stats-
[This is pretty well lifted from Scientific American.]
http://heartdisease.about.com/
http://www.scientificamerican.
even if the findings of the meta-analysis are accurate and the side effects are rare, "one should question whether it is cost-effective" to put millions of people on the drugs for a small potential benefit, says James Liao, an expert in vascular medicine at Brigham and Women's Hospital in Boston. Generic low-cost versions of the drugs are available—Walmart sells a month's supply of low-dose lovastatin for $4—but many consumers choose costlier brand name options. In 2011, for instance, Americans spent $4.4 billion on AstraZeneca's Crestor and $7.7 billion on Pfizer's Lipitor.
Researcher Colin Baigent, said "We've been taught over the years that high cholesterol is the thing that matters; you mustn't have high cholesterol."
He added "But what we've actually learned is that, whatever your level of cholesterol, reducing it further is beneficial. Whatever your level of risk, the benefits greatly exceed any known hazard."
http://www.diabetes.co.uk/
No comments:
Post a Comment